🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against superbug strains of the bacteria, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are on the rise worldwide, with figures suggesting over 82 million instances annually. Especially elevated rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Public health authorities are particularly alarmed about the surge in antibiotic-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program showed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Receive Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts believe that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone marks a major breakthrough in the management of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Results and Global Access

Based on findings published in a major medical journal, the new drug successfully treated more than 90% of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which combines an injection and a pill. The trial involved nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to make available and distribute the drug in numerous developing nations.

Doctors on the front lines have voiced hope. Access to a single-dose, oral treatment of this kind is described as a "revolutionary step" for managing the epidemic. This is viewed as vital to alleviate the strain of the infection for individuals and to halt the transmission of untreatable gonorrhoea globally.